In the pre-treatment setting, biomarkers associated with an improved tumor response were as follows: lower levels of CTLA4+ Treg, BCL-2 expression, high expression of Ku70 and MIB-1(Ki-67), low expression of nuclear β-catenin and MRI modifications (CBPFM Dp mean value and SD and VARPRO Dp mean value). The gene discussed is XRCC6; the disease is neoplasm.